$2.7 Billion Biopharmaceutical Merger

November 5, 2015

Cleary Gottlieb is representing Goldman Sachs, as financial advisor to ZS Pharma in its all-cash sale to AstraZeneca. The transaction is valued at approximately $2.7 billion. The deal signed on November 5, 2015 and is expected to close by the end of 2015.

ZS Pharma is a biopharmaceutical company dedicated to challenging the status quo in disease states where therapeutic options have been limited.

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases.